Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 1 Oct 2013

Bon Isabella, Clò Alberto, Borderi Marco, Colangeli Vincenzo, Calza Leonardo, Morini Silvia, Miserocchi Anna, Cricca Monica, Gibellini Davide, Re Maria Carla

Abstract excerpt

OBJECTIVES: Maraviroc currently represents an important antiretroviral drug for multi-experienced and viremic HIV patients. This study focused on two main points: (1) determining the prevalence of R5 and X4 HIV strains in antiretroviral-experienced patients using two main tests currently in use to determine viral tropism, and (2) the follow-up to 3 years of a limited number of patients who started a new...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CCR5 Receptor Antagonists
Share to Cyclohexanes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Substitution

Share to HIV Fusion Inhibitors

Share to Receptors, CCR5

Share to Triazoles

Share to Viral Load

Share to Viral Tropism

Source

Identifiers

PMID: 23597487
DOI: 10.1016/j.ijid.2013.02.020

Genes

CCR5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.PMID 23597487Read ↗

Prevalence of R5 and X4 HIV variants in antiretroviral treatment experienced patients with virologic failure.Semantic proximity Read ↗

Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists.Semantic proximity Read ↗

Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.Semantic proximity Read ↗

Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice.Semantic proximity Read ↗

<i>In vitro</i> phenotypic susceptibility of HIV-1 non-group M to CCR5 inhibitor (Maraviroc): TROPI-CO studySemantic proximity Read ↗

[Methods for determining viral tropism: genotype and phenotype tests].Semantic proximity Read ↗

Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.Semantic proximity Read ↗

Maraviroc: a review of its use in HIV infection and beyond.Semantic proximity Read ↗

Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.Semantic proximity Read ↗

Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.Semantic proximity Read ↗

In vitro phenotypic susceptibility of HIV-1 non-group M to CCR5 inhibitor (maraviroc): TROPI-CO study.Semantic proximity Read ↗

Genotypic tropism testing: evidence-based or leap of faith?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.